Skip to main content
Top
Published in: CNS Drugs 5/2001

01-05-2001 | Therapy in Practice

Psychiatric Disorders Associated with Cushing’s Syndrome

Epidemiology, Pathophysiology and Treatment

Authors: Dr Nicoletta Sonino, Giovanni A. Fava

Published in: CNS Drugs | Issue 5/2001

Login to get access

Abstract

Cushing’s syndrome is caused by a chronic excess of glucocorticoids. A number of psychiatric and psychological disturbances may be associated with the condition, regardless of its aetiology. Major depression is the most common co-morbid disorder. Other psychopathological aspects of Cushing’s syndrome in adults include mania, anxiety disorders and cognitive dysfunction.
The presence of depression connotes a severe clinical presentation and, in patients with hypothalamic-pituitary forms of Cushing’s syndrome, is prognostically useful. Inhibitors of corticosteroid production (e.g. ketoconazole, metyrapone, aminoglutethimide), rather than antidepressant drugs, are generally successful in relieving depressive symptoms, as well as other disabling symptoms. These drugs can be used to control symptoms prior to surgical treatment of Cushing’s syndrome.
Long-standing hypercortisolism may cause some degree of irreversible pathological damage and induce highly individualised affective responses based on each patient’s psychological assets and liabilities. As a result, upon normalisation of cortisol levels, treatment may still be required, and should encompass both psychotherapeutic strategies (particularly cognitive-behavioural therapies that have been found to be effective in affective disorders) and psychotropic drug treatment [antidepressants such as tricyclic agents and selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors]. In patients with severe anxiety, benzodiazepines (e.g. clonazepam in small doses) may also be helpful.
Literature
1.
go back to reference Sonino N, Fava GA. Psychological aspects of endocrine disease. Clin Endocrinol (Oxf) 1998; 49: 1–7CrossRef Sonino N, Fava GA. Psychological aspects of endocrine disease. Clin Endocrinol (Oxf) 1998; 49: 1–7CrossRef
2.
go back to reference Sonino N, Fava GA. Psychosomatic aspects of Cushing’s disease. Psychother Psychosom 1998; 67: 140–6PubMedCrossRef Sonino N, Fava GA. Psychosomatic aspects of Cushing’s disease. Psychother Psychosom 1998; 67: 140–6PubMedCrossRef
3.
go back to reference Boscaro M, Barzon L, Sonino N. The diagnosis of Cushing’s syndrome: atypical presentations and laboratory pitfalls. Arch Intern Med 2000; 160: 3045–53PubMedCrossRef Boscaro M, Barzon L, Sonino N. The diagnosis of Cushing’s syndrome: atypical presentations and laboratory pitfalls. Arch Intern Med 2000; 160: 3045–53PubMedCrossRef
4.
5.
go back to reference Crosby SR, Steward MF, Ratcliffe JD, et al. Direct measurement of the precursors of adrenocorticotropin in human plasma by two-site immunoradiometric assay. J Clin Endocrinol Metab 1998; 67: 1272–7CrossRef Crosby SR, Steward MF, Ratcliffe JD, et al. Direct measurement of the precursors of adrenocorticotropin in human plasma by two-site immunoradiometric assay. J Clin Endocrinol Metab 1998; 67: 1272–7CrossRef
6.
go back to reference Lowry PJ, Linton EA, Hodgkinson SC. Analysis of peptide hormones of the hypothalamic pituitary adrenal axis using ‘two-site’ immunoradiometric assays. Horm Res 1989; 32: 25–9PubMedCrossRef Lowry PJ, Linton EA, Hodgkinson SC. Analysis of peptide hormones of the hypothalamic pituitary adrenal axis using ‘two-site’ immunoradiometric assays. Horm Res 1989; 32: 25–9PubMedCrossRef
7.
go back to reference Samuels MH, Loriaux LD. Cushing’ s syndrome and the nodular adrenal gland. Endocrinol Metab Clin North Am 1994; 23: 555–69PubMed Samuels MH, Loriaux LD. Cushing’ s syndrome and the nodular adrenal gland. Endocrinol Metab Clin North Am 1994; 23: 555–69PubMed
8.
go back to reference Lacroix A, Boite E, Tremblay J, et al. Gastric inhibitory polypeptide-dependent Cortisol hypersecretion: a new cause of Cushing’s syndrome. N Engl J Med 1992; 327: 974–80PubMedCrossRef Lacroix A, Boite E, Tremblay J, et al. Gastric inhibitory polypeptide-dependent Cortisol hypersecretion: a new cause of Cushing’s syndrome. N Engl J Med 1992; 327: 974–80PubMedCrossRef
9.
go back to reference Reznik Y, Allali-Zerah V, Chayavialle JA, et al. Food dependent Cushing’s syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 1992; 327: 981–6PubMedCrossRef Reznik Y, Allali-Zerah V, Chayavialle JA, et al. Food dependent Cushing’s syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 1992; 327: 981–6PubMedCrossRef
10.
go back to reference Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotrophin-releasing hormone for the differential diagnosis of Cushing’s syndrome. N Engl J Med 1991; 325: 897–905PubMedCrossRef Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotrophin-releasing hormone for the differential diagnosis of Cushing’s syndrome. N Engl J Med 1991; 325: 897–905PubMedCrossRef
11.
go back to reference White FE, White MC, Drury PL, et al. Value of computed tomography of the abdomen and chest in investigations of Cushing’s syndrome. BMJ 1982; 284: 771–4PubMedCrossRef White FE, White MC, Drury PL, et al. Value of computed tomography of the abdomen and chest in investigations of Cushing’s syndrome. BMJ 1982; 284: 771–4PubMedCrossRef
12.
go back to reference Buchfelder M, Nistor R, Fahlbusch R, et al. The accuracy of CT and MR evaluation of the sella turcica for detection of adrenocorticotropin hormone-secreting adenomas in Cushing’s disease. Am J Neuroradiol 1993; 4: 1183–90 Buchfelder M, Nistor R, Fahlbusch R, et al. The accuracy of CT and MR evaluation of the sella turcica for detection of adrenocorticotropin hormone-secreting adenomas in Cushing’s disease. Am J Neuroradiol 1993; 4: 1183–90
13.
go back to reference Colombo L, Loli P, Vignati F, et al. MR of corticotropin-secreting pituitary microadenomas. Am J Neuroradiol 1994; 15: 1591–5PubMed Colombo L, Loli P, Vignati F, et al. MR of corticotropin-secreting pituitary microadenomas. Am J Neuroradiol 1994; 15: 1591–5PubMed
14.
go back to reference James RA. Octreotide and ectopic Cushing’s syndrome: a commentary. Clin Endocrinol 1998; 49: 419–20CrossRef James RA. Octreotide and ectopic Cushing’s syndrome: a commentary. Clin Endocrinol 1998; 49: 419–20CrossRef
15.
go back to reference de Herder WW, Lamberts SWJ. Tumor localization: the ectopic ACTH syndrome. J Clin Endocrinol Metab 1999; 84: 1184–5PubMedCrossRef de Herder WW, Lamberts SWJ. Tumor localization: the ectopic ACTH syndrome. J Clin Endocrinol Metab 1999; 84: 1184–5PubMedCrossRef
16.
17.
go back to reference Ross EJ, Linch DC. Cushing’s syndrome — killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; II: 646–9CrossRef Ross EJ, Linch DC. Cushing’s syndrome — killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; II: 646–9CrossRef
18.
go back to reference Sonino N, Boscaro M, Fallo F, et al. A clinical index for rating severity in Cushing’s syndrome. Psychother Psychosom 2000; 69: 216–0PubMedCrossRef Sonino N, Boscaro M, Fallo F, et al. A clinical index for rating severity in Cushing’s syndrome. Psychother Psychosom 2000; 69: 216–0PubMedCrossRef
19.
go back to reference Sonino N, Zielezny M, Fava GA, et al. Risk factors and long-term outcome in pituitary-dependent Cushing’s disease. J Clin Endocrinol Metab 1996; 81: 2647–52PubMedCrossRef Sonino N, Zielezny M, Fava GA, et al. Risk factors and long-term outcome in pituitary-dependent Cushing’s disease. J Clin Endocrinol Metab 1996; 81: 2647–52PubMedCrossRef
20.
go back to reference Sonino N, Boscaro M. Medical therapy for Cushing’s disease. Endocrinol Metab Clin North Am 1999; 28: 211–2PubMedCrossRef Sonino N, Boscaro M. Medical therapy for Cushing’s disease. Endocrinol Metab Clin North Am 1999; 28: 211–2PubMedCrossRef
21.
go back to reference Sonino N, Fava GA, Fallo F, et al. Effect of serotonin antagonists ritanserin and ketanserin in Cushing’s disease. Pituitary 2000; 3: 55–60PubMedCrossRef Sonino N, Fava GA, Fallo F, et al. Effect of serotonin antagonists ritanserin and ketanserin in Cushing’s disease. Pituitary 2000; 3: 55–60PubMedCrossRef
22.
go back to reference Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987; 317: 812–18PubMedCrossRef Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 1987; 317: 812–18PubMedCrossRef
23.
go back to reference Whitlock FA. Symptomatic affective disorders. Sydney: Academic Press, 1982 Whitlock FA. Symptomatic affective disorders. Sydney: Academic Press, 1982
24.
go back to reference Haskett RF. Diagnostic categorization of psychiatric disturbance in Cushing’s syndrome. Am J Psychiatry 1985; 142: 911–16PubMed Haskett RF. Diagnostic categorization of psychiatric disturbance in Cushing’s syndrome. Am J Psychiatry 1985; 142: 911–16PubMed
25.
go back to reference Hudson JI, Hudson MS, Griffing GT, et al. Phenomenology and family history of affective disorder in Cushing’ s disease. Am J Psychiatry 1987; 144: 951–3PubMed Hudson JI, Hudson MS, Griffing GT, et al. Phenomenology and family history of affective disorder in Cushing’ s disease. Am J Psychiatry 1987; 144: 951–3PubMed
26.
go back to reference Loosen PT, Chambliss B, de Bold CR, et al. Psychiatric phenomenology in Cushing’s disease. Pharmacopsychiatry 1992; 25: 192–8PubMedCrossRef Loosen PT, Chambliss B, de Bold CR, et al. Psychiatric phenomenology in Cushing’s disease. Pharmacopsychiatry 1992; 25: 192–8PubMedCrossRef
27.
go back to reference Sonino N, Fava GA, Belluardo P, et al. Course of depression in Cushing’s syndrome: response to treatment and comparison with Graves’ disease. Horm Res 1993; 39: 202–6PubMedCrossRef Sonino N, Fava GA, Belluardo P, et al. Course of depression in Cushing’s syndrome: response to treatment and comparison with Graves’ disease. Horm Res 1993; 39: 202–6PubMedCrossRef
28.
go back to reference Kelly WF. Psychiatric aspects of Cushing’s syndrome. Q J Med 1996; 89: 543–1CrossRef Kelly WF. Psychiatric aspects of Cushing’s syndrome. Q J Med 1996; 89: 543–1CrossRef
29.
go back to reference Sonino N, Fava GA, Raffi AR, et al. Clinical correlates of major depression in Cushing’s disease. Psychopathology 1998; 31: 302–6PubMedCrossRef Sonino N, Fava GA, Raffi AR, et al. Clinical correlates of major depression in Cushing’s disease. Psychopathology 1998; 31: 302–6PubMedCrossRef
30.
go back to reference Dorn LD, Burgess ES, Dubbert B, et al. Psychopathology in patients with endogenous Cushing’s syndrome: atypical or melancholic features. Clin Endocrinol 1995; 43: 433–2CrossRef Dorn LD, Burgess ES, Dubbert B, et al. Psychopathology in patients with endogenous Cushing’s syndrome: atypical or melancholic features. Clin Endocrinol 1995; 43: 433–2CrossRef
31.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
33.
go back to reference Fava GA, Sonino N. Depression associated with medical illness. CNS Drugs 1996; 5: 175–89CrossRef Fava GA, Sonino N. Depression associated with medical illness. CNS Drugs 1996; 5: 175–89CrossRef
34.
go back to reference Starkman MN, Schteingart DE, Schork MA. Depressed mood and other psychiatric manifestations of Cushing’s syndrome. Psychosom Med 1981; 43: 3–18PubMed Starkman MN, Schteingart DE, Schork MA. Depressed mood and other psychiatric manifestations of Cushing’s syndrome. Psychosom Med 1981; 43: 3–18PubMed
35.
go back to reference Lam RW, Stewart JN. The validity of atypical depression in DSM-IV. Compr Psychiatry 1996; 37: 375–83PubMedCrossRef Lam RW, Stewart JN. The validity of atypical depression in DSM-IV. Compr Psychiatry 1996; 37: 375–83PubMedCrossRef
37.
go back to reference Fava GA, Mangelli L. Subclinical symptoms of panic disorder. Psychother Psychosom 1999; 68: 281–9PubMedCrossRef Fava GA, Mangelli L. Subclinical symptoms of panic disorder. Psychother Psychosom 1999; 68: 281–9PubMedCrossRef
38.
go back to reference Schneider G, Kruse A, Nehen HG, et al. The prevalence and differential diagnosis of subclinical depressive syndromes in inpatients 60 years old and older. Psychother Psychosom 2000; 69: 251–60PubMedCrossRef Schneider G, Kruse A, Nehen HG, et al. The prevalence and differential diagnosis of subclinical depressive syndromes in inpatients 60 years old and older. Psychother Psychosom 2000; 69: 251–60PubMedCrossRef
39.
go back to reference Fava GA, Sonino N. Psychosomatic medicine: emerging trends and perspectives. Psychother Psychosom 2000; 69: 184–97PubMedCrossRef Fava GA, Sonino N. Psychosomatic medicine: emerging trends and perspectives. Psychother Psychosom 2000; 69: 184–97PubMedCrossRef
40.
go back to reference Meyer T, Klemme H, Herrmann C. Depression but not anxiety is a significant predictor of physicians’ assessment of medical status in physically ill patients. Psychother Psychosom 2000; 69: 147–54PubMedCrossRef Meyer T, Klemme H, Herrmann C. Depression but not anxiety is a significant predictor of physicians’ assessment of medical status in physically ill patients. Psychother Psychosom 2000; 69: 147–54PubMedCrossRef
41.
go back to reference Fava M, Rankin MA, Wright JE, et al. Anxiety disorders in major depression. Comp Psychiatry 2000; 41: 97–102CrossRef Fava M, Rankin MA, Wright JE, et al. Anxiety disorders in major depression. Comp Psychiatry 2000; 41: 97–102CrossRef
42.
go back to reference Starkman MN, Schteingart DE, Schork MA. Correlation of bedside cognitive and neuropsychological tests in patients with Cushing’s syndrome. Psychosomatics 1986; 27: 508–11PubMedCrossRef Starkman MN, Schteingart DE, Schork MA. Correlation of bedside cognitive and neuropsychological tests in patients with Cushing’s syndrome. Psychosomatics 1986; 27: 508–11PubMedCrossRef
43.
go back to reference Mauri M, Sinforiani E, Bono G, et al. Memory impairment in Cushing’s disease. Acta Neurol Scand 1993; 87: 52–5PubMedCrossRef Mauri M, Sinforiani E, Bono G, et al. Memory impairment in Cushing’s disease. Acta Neurol Scand 1993; 87: 52–5PubMedCrossRef
44.
go back to reference Forget H, Lacroix A, Somma M, et al. Cognitive decline in patients with Cushing’s syndrome. J Internat Neuropsychol Soc 2000; 6: 20–9 Forget H, Lacroix A, Somma M, et al. Cognitive decline in patients with Cushing’s syndrome. J Internat Neuropsychol Soc 2000; 6: 20–9
45.
go back to reference Simmons NE, Do HM, Lipper MH, et al. Cerebral atrophy in Cushing’s disease. Surg Neurol 2000; 53: 72–6PubMedCrossRef Simmons NE, Do HM, Lipper MH, et al. Cerebral atrophy in Cushing’s disease. Surg Neurol 2000; 53: 72–6PubMedCrossRef
46.
go back to reference Sonino N. From the lesson of Harvey Cushing to current knowledge: psychosocial aspects of endocrine disease. Psychother Psychosom 1997; 66: 113–6PubMedCrossRef Sonino N. From the lesson of Harvey Cushing to current knowledge: psychosocial aspects of endocrine disease. Psychother Psychosom 1997; 66: 113–6PubMedCrossRef
47.
go back to reference Cushing H. Psychic disturbances associated with disorders of the ductless glands. Am J Insanity 1913; 69: 965–0 Cushing H. Psychic disturbances associated with disorders of the ductless glands. Am J Insanity 1913; 69: 965–0
48.
go back to reference Trethowan WH, Cobb S. Neuropsychiatric aspects of Cushing’s syndrome. AMA Arch Neurol Psychiat 1952; 67: 283–309CrossRef Trethowan WH, Cobb S. Neuropsychiatric aspects of Cushing’s syndrome. AMA Arch Neurol Psychiat 1952; 67: 283–309CrossRef
49.
go back to reference Gifford S, Gunderson JG. Cushing’ s disease as a psychosomatic disorder. Medicine 1970; 49: 397–409PubMedCrossRef Gifford S, Gunderson JG. Cushing’ s disease as a psychosomatic disorder. Medicine 1970; 49: 397–409PubMedCrossRef
50.
go back to reference Cohen SI. Cushing’ s syndrome. A psychiatric study of 29 patients. Br J Psychiatry 1988; 120–4 Cohen SI. Cushing’ s syndrome. A psychiatric study of 29 patients. Br J Psychiatry 1988; 120–4
51.
go back to reference Sonino N, Fava GA, Grandi S, et al. Stressful life events in the pathogenesis of Cushing’s syndrome. Clin Endocrinol 1988; 29: 617–23CrossRef Sonino N, Fava GA, Grandi S, et al. Stressful life events in the pathogenesis of Cushing’s syndrome. Clin Endocrinol 1988; 29: 617–23CrossRef
52.
go back to reference Sonino N, Fava GA, Boscaro M. A role for life events in the pathogenesis of Cushing’s disease. Clin Endocrinol 1993; 38: 261–4CrossRef Sonino N, Fava GA, Boscaro M. A role for life events in the pathogenesis of Cushing’s disease. Clin Endocrinol 1993; 38: 261–4CrossRef
54.
go back to reference Mazet Ph, Simon D, Luton JP, et al. Syndrome de Cushing: Symptomatologie psychique et personalité de 50 malades. Nouv Press Med 1988; 10: 2565–70 Mazet Ph, Simon D, Luton JP, et al. Syndrome de Cushing: Symptomatologie psychique et personalité de 50 malades. Nouv Press Med 1988; 10: 2565–70
55.
56.
go back to reference Sonino N, Girelli ME, Boscaro M, et al. Life events in the pathogenesis of Graves’ disease. Acta Endocrinol 1993; 128: 293–6PubMed Sonino N, Girelli ME, Boscaro M, et al. Life events in the pathogenesis of Graves’ disease. Acta Endocrinol 1993; 128: 293–6PubMed
57.
go back to reference Radosavljevic VR, Jankovic SN, Marinkovic JM. Stressful life events in the pathogenesis of Graves’ disease. Eur J Endocrinol 1996; 134: 699–701PubMedCrossRef Radosavljevic VR, Jankovic SN, Marinkovic JM. Stressful life events in the pathogenesis of Graves’ disease. Eur J Endocrinol 1996; 134: 699–701PubMedCrossRef
58.
go back to reference Kung AWC. Life events, daily stresses and coping in patients with Graves’ disease. Clin Endocrinol 1995; 42: 303–8CrossRef Kung AWC. Life events, daily stresses and coping in patients with Graves’ disease. Clin Endocrinol 1995; 42: 303–8CrossRef
60.
go back to reference Biondi M, Picardi A. Psychological stress and neuroendocrine function in humans. Psychother Psychosom 1999; 68: 114–50PubMedCrossRef Biondi M, Picardi A. Psychological stress and neuroendocrine function in humans. Psychother Psychosom 1999; 68: 114–50PubMedCrossRef
61.
go back to reference Sonino N, Fava GA. Serotonin, Cushing’s disease and depression. Psychother Psychosom 1996; 65: 63–5PubMedCrossRef Sonino N, Fava GA. Serotonin, Cushing’s disease and depression. Psychother Psychosom 1996; 65: 63–5PubMedCrossRef
62.
go back to reference de Kloet ER, Rots NY, Cools AR. Brain-corticosteroid hormone dialogue: slow and persistent. Cell Mol Neurobiol 1996; 16: 345–56CrossRef de Kloet ER, Rots NY, Cools AR. Brain-corticosteroid hormone dialogue: slow and persistent. Cell Mol Neurobiol 1996; 16: 345–56CrossRef
63.
go back to reference Seeman T, McEwen BS. Impact of social environment characteristics on neuroendocrine regulation. Psychosom Med 1996; 58:459–71PubMed Seeman T, McEwen BS. Impact of social environment characteristics on neuroendocrine regulation. Psychosom Med 1996; 58:459–71PubMed
64.
go back to reference Heim C, Owens MJ, Plotsky PM, et al. Persistent changes in corticotrophin-releasing factor systems due to early life stress. Psychopharmacol Bull1997; 33: 185–92PubMed Heim C, Owens MJ, Plotsky PM, et al. Persistent changes in corticotrophin-releasing factor systems due to early life stress. Psychopharmacol Bull1997; 33: 185–92PubMed
65.
go back to reference Burgess E, Dorn LD, Haaga DAF, et al. Sociotropy, autonomy, stress, and depression in Cushing syndrome. J Nerv Ment Dis 1996; 184: 362–7PubMedCrossRef Burgess E, Dorn LD, Haaga DAF, et al. Sociotropy, autonomy, stress, and depression in Cushing syndrome. J Nerv Ment Dis 1996; 184: 362–7PubMedCrossRef
67.
go back to reference Kelly WF, Kelly MJ, Faragher B. A prospective study of psychiatric and psychological aspects of Cushing’s syndrome. Clin Endocrinol 1996; 45: 715–20CrossRef Kelly WF, Kelly MJ, Faragher B. A prospective study of psychiatric and psychological aspects of Cushing’s syndrome. Clin Endocrinol 1996; 45: 715–20CrossRef
68.
go back to reference Dorn LD, Burgess ES, Friedman TC, et al. The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 1997; 82: 912–9PubMedCrossRef Dorn LD, Burgess ES, Friedman TC, et al. The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 1997; 82: 912–9PubMedCrossRef
69.
go back to reference Voigt KH, Bossert S, Bretschneider S, et al. Disturbed Cortisol secretion in man. Psychiatry Res 1985; 15: 341–50PubMedCrossRef Voigt KH, Bossert S, Bretschneider S, et al. Disturbed Cortisol secretion in man. Psychiatry Res 1985; 15: 341–50PubMedCrossRef
70.
go back to reference Taft P, Martin FIR, Melick R. Cushing’ s syndrome. A review of the response to treatment in 42 patients. Australas Ann Med 1970; 4: 295–303 Taft P, Martin FIR, Melick R. Cushing’ s syndrome. A review of the response to treatment in 42 patients. Australas Ann Med 1970; 4: 295–303
71.
go back to reference Sonino N, Fallo F, Opocher G, et al. Hypertension in Cushing’s syndrome. Med Sci Res 1992; 20: 431–4 Sonino N, Fallo F, Opocher G, et al. Hypertension in Cushing’s syndrome. Med Sci Res 1992; 20: 431–4
72.
go back to reference Fallo F, Sonino N, Barzon L, et al. Effects of surgical treatment on hypertension in Cushing’s syndrome. Am JHypertens 1996; 9: 77–80CrossRef Fallo F, Sonino N, Barzon L, et al. Effects of surgical treatment on hypertension in Cushing’s syndrome. Am JHypertens 1996; 9: 77–80CrossRef
73.
go back to reference Regenstein QR, Rose LI, Williams GH. Psychopathology in Cushing’s syndrome. Arch Intern Med 1972; 130: 114–7CrossRef Regenstein QR, Rose LI, Williams GH. Psychopathology in Cushing’s syndrome. Arch Intern Med 1972; 130: 114–7CrossRef
74.
go back to reference Jacobs BL, van Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 2000; 5: 262–9PubMedCrossRef Jacobs BL, van Praag H, Gage FH. Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol Psychiatry 2000; 5: 262–9PubMedCrossRef
75.
go back to reference Starkman MN, Giordani B, Gerbaski SS, et al. Decrease in cortical reverses human hippocampal atrophy following treatment of Cushing’s disease. Biol Psychiatry 1999; 46: 1595–602PubMedCrossRef Starkman MN, Giordani B, Gerbaski SS, et al. Decrease in cortical reverses human hippocampal atrophy following treatment of Cushing’s disease. Biol Psychiatry 1999; 46: 1595–602PubMedCrossRef
76.
go back to reference Jeffcoate WJ, Silverstone JT, Edwards CRW, et al. Psychiatric manifestations of Cushing’s syndrome: response to lowering of plasma cortisol. Q J Med 1979, 48: 465–72PubMed Jeffcoate WJ, Silverstone JT, Edwards CRW, et al. Psychiatric manifestations of Cushing’s syndrome: response to lowering of plasma cortisol. Q J Med 1979, 48: 465–72PubMed
77.
go back to reference Kramlinger KG, Peterson GC, Watson PK,et al. Metyrapone for depression and delirium secondary to Cushing’s syndrome. Psychosomatics 1985; 26: 67–71PubMedCrossRef Kramlinger KG, Peterson GC, Watson PK,et al. Metyrapone for depression and delirium secondary to Cushing’s syndrome. Psychosomatics 1985; 26: 67–71PubMedCrossRef
78.
go back to reference van der Lely AJ, Foeken K, van der Mast RC, et al. Rapid reversal of acute psychosis in the Cushing’s syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med 1991; 114: 143–4PubMed van der Lely AJ, Foeken K, van der Mast RC, et al. Rapid reversal of acute psychosis in the Cushing’s syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med 1991; 114: 143–4PubMed
79.
go back to reference Sonino N, Boscaro M, Ambroso G, et al. Prolonged treatment of Cushing’s disease with metyrapone and aminoglutethimide. IRCS Med Sci 1986; 14: 485–6 Sonino N, Boscaro M, Ambroso G, et al. Prolonged treatment of Cushing’s disease with metyrapone and aminoglutethimide. IRCS Med Sci 1986; 14: 485–6
80.
go back to reference Pelton GH. Antiglucocorticoidid medication for the treatment of depression. Psychiat Ann 2000; 30: 139–46 Pelton GH. Antiglucocorticoidid medication for the treatment of depression. Psychiat Ann 2000; 30: 139–46
81.
go back to reference Starkman MN, Schteingart DE, Schork MA. Cushing’s syndrome after treatment. Psychiatry Res 1986; 17: 177–8CrossRef Starkman MN, Schteingart DE, Schork MA. Cushing’s syndrome after treatment. Psychiatry Res 1986; 17: 177–8CrossRef
82.
go back to reference Starkman MN, Gebarski SS, Berent S, et al. Hippocampal formation volume, memory dysfunction, and Cortisol levels in patients with Cushing’s syndrome. Biol Psychiatry 1992; 32: 756–65PubMedCrossRef Starkman MN, Gebarski SS, Berent S, et al. Hippocampal formation volume, memory dysfunction, and Cortisol levels in patients with Cushing’s syndrome. Biol Psychiatry 1992; 32: 756–65PubMedCrossRef
83.
go back to reference Momose KJ, Kjellberg RN, Kliman B. High incidence of cortical atrophy of the cerebral and cerebellar hemispheres in Cushing’s disease. Radiology 1971; 99: 341–8PubMed Momose KJ, Kjellberg RN, Kliman B. High incidence of cortical atrophy of the cerebral and cerebellar hemispheres in Cushing’s disease. Radiology 1971; 99: 341–8PubMed
84.
go back to reference Dubrovsky B. Effects of adrenal cortex hormones on limbic structures. J Psychiat Neurosci 1993; 18: 4–16 Dubrovsky B. Effects of adrenal cortex hormones on limbic structures. J Psychiat Neurosci 1993; 18: 4–16
Metadata
Title
Psychiatric Disorders Associated with Cushing’s Syndrome
Epidemiology, Pathophysiology and Treatment
Authors
Dr Nicoletta Sonino
Giovanni A. Fava
Publication date
01-05-2001
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 5/2001
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200115050-00003

Other articles of this Issue 5/2001

CNS Drugs 5/2001 Go to the issue

Therapy in Practice

Psychogenic Excoriation